JP2005501856A5 - - Google Patents

Download PDF

Info

Publication number
JP2005501856A5
JP2005501856A5 JP2003521230A JP2003521230A JP2005501856A5 JP 2005501856 A5 JP2005501856 A5 JP 2005501856A5 JP 2003521230 A JP2003521230 A JP 2003521230A JP 2003521230 A JP2003521230 A JP 2003521230A JP 2005501856 A5 JP2005501856 A5 JP 2005501856A5
Authority
JP
Japan
Prior art keywords
mmol
amine
added
mixture
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003521230A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501856A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/021317 external-priority patent/WO2003016307A1/en
Publication of JP2005501856A publication Critical patent/JP2005501856A/ja
Publication of JP2005501856A5 publication Critical patent/JP2005501856A5/ja
Pending legal-status Critical Current

Links

JP2003521230A 2001-08-14 2002-08-06 β3アドレナリン作動性アゴニスト Pending JP2005501856A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31227501P 2001-08-14 2001-08-14
PCT/US2002/021317 WO2003016307A1 (en) 2001-08-14 2002-08-06 β3 ADRENERGIC AGONISTS

Publications (2)

Publication Number Publication Date
JP2005501856A JP2005501856A (ja) 2005-01-20
JP2005501856A5 true JP2005501856A5 (enExample) 2006-01-05

Family

ID=23210688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003521230A Pending JP2005501856A (ja) 2001-08-14 2002-08-06 β3アドレナリン作動性アゴニスト

Country Status (7)

Country Link
US (1) US7208505B2 (enExample)
EP (1) EP1421078B1 (enExample)
JP (1) JP2005501856A (enExample)
AT (1) ATE340794T1 (enExample)
DE (1) DE60215028T2 (enExample)
ES (1) ES2272749T3 (enExample)
WO (1) WO2003016307A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60215028T2 (de) 2001-08-14 2007-03-15 Eli Lilly And Co., Indianapolis Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
DE60225174T2 (de) * 2001-11-20 2009-02-12 Eli Lilly And Co., Indianapolis Beta-3 adrenergische agonisten
JP2005514366A (ja) * 2001-11-20 2005-05-19 イーライ・リリー・アンド・カンパニー 3−置換オキシインドールβ3アゴニスト
EP1467733A1 (en) 2002-01-11 2004-10-20 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7622491B2 (en) * 2004-08-13 2009-11-24 Metabolex Inc. Modulators of PPAR and methods of their preparation
DE102005052127A1 (de) * 2005-10-28 2007-05-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue indol-haltige Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2631232A1 (en) 2005-12-01 2007-06-07 F. Hoffmann-La Roche Ag Novel vinylogous acids derivatives
AU2007257882B2 (en) 2006-06-12 2011-09-08 Secura Bio Inc. Process for making salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624395A5 (enExample) 1976-01-08 1981-07-31 Ciba Geigy Ag
US4314943A (en) 1977-07-13 1982-02-09 Mead Johnson & Company Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols
US4234595A (en) 1977-07-13 1980-11-18 Mead Johnson & Company 3-Indolyl-tertiary butylaminopropanols
CA1116598A (en) * 1977-07-13 1982-01-19 William T. Comer 3-indolyl-tertiary butylaminopropanols
JPS6010021B2 (ja) 1979-01-31 1985-03-14 田辺製薬株式会社 新規ベンジルアルコ−ル誘導体及びその製法
DE3423429A1 (de) * 1984-06-26 1986-01-02 Beiersdorf Ag, 2000 Hamburg Substituierte phenoxyalkylaminopropanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
DE3426419A1 (de) 1984-07-18 1986-01-23 Boehringer Mannheim Gmbh, 6800 Mannheim Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US4728651A (en) 1985-10-24 1988-03-01 Hoechst-Roussel Pharmaceuticals Inc. Antihypertensive thieno-isoxazoles and -pyrazoles
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
NO303782B1 (no) 1994-03-23 1998-08-31 Sankyo Co Tiazolidin- og oksazolidinderivater og farmas°ytiske preparater inneholdende slike, samt deres anvendelse til fremstilling av medikamenter
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US6075040A (en) 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
JP2000511903A (ja) 1996-06-07 2000-09-12 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のための選択性β▲下3▼作動薬としてのオキサジアゾール・ベンゼンスルホンアミド
EP0827746B1 (en) 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
IL131130A0 (en) 1997-01-28 2001-01-28 Merck & Co Inc Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
US6011048A (en) 1997-01-28 2000-01-04 Merck & Co., Inc. Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity
AUPP796798A0 (en) 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
JP2003055344A (ja) 1999-01-29 2003-02-26 Dainippon Pharmaceut Co Ltd 3,7−ジ置換インドール誘導体及びそれを含有する医薬組成物
WO2001007026A2 (en) 1999-07-22 2001-02-01 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
WO2001035947A2 (en) 1999-11-15 2001-05-25 Eli Lilly And Company Treating wasting syndromes with aryloxy propanolamines
WO2001036412A1 (en) 1999-11-15 2001-05-25 Eli Lilly And Company Process for the preparation of aryloxy propanolamines
AU2001236471A1 (en) 2000-01-18 2001-07-31 Neurogen Corporation Imidazopyridines and related azacyclic derivatives as selective modulators of bradykinin b2 receptors
GB0015727D0 (en) 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
HUP0301329A2 (hu) * 2000-07-13 2003-08-28 Eli Lilly And Co. Béta3 Adrenergiás agonisták, valamint ezen vegyületeket tartalmazó gyógyászati készítmények és eljárás e vegyületek előállítására
DE60120748T2 (de) 2000-11-10 2007-05-16 Eli Lilly And Co., Indianapolis 3-substituierte oxindolderivate als beta-3-agonisten
US6911463B2 (en) 2001-08-14 2005-06-28 Eli Lilly And Company 3-substituted oxindole β-3 agonists
DE60215028T2 (de) 2001-08-14 2007-03-15 Eli Lilly And Co., Indianapolis Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
JP2005514366A (ja) 2001-11-20 2005-05-19 イーライ・リリー・アンド・カンパニー 3−置換オキシインドールβ3アゴニスト
DE60225174T2 (de) 2001-11-20 2009-02-12 Eli Lilly And Co., Indianapolis Beta-3 adrenergische agonisten

Similar Documents

Publication Publication Date Title
EP1421078B1 (en) Indole derivatives as beta-3 adrenergic agonists for the treatment of type 2 diabetes
EP1444224B1 (en) 3-substituted oxindole beta-3 agonists
JP4988128B2 (ja) β3アドレナリン作動性アゴニスト
RU2263674C2 (ru) Бензимидазольное производное, ингибитор человеческой химазы, терапевтический агент и фармацевтическая композиция на его основе
US7071208B2 (en) β3 Adrenergic agonists
WO2000078726A1 (en) Imidazoline derivatives for the treatment of diabetes, especially type ii diabetes
NZ318718A (en) Selective <beta><sub>3</sub> adrenergic receptor agonists
WO2003044016A1 (en) 3-SUBSTITUTED OXINDOLE β3 AGONISTS
US6617347B1 (en) Selective β3 adrenergic agonists
KR20080065674A (ko) 신규한 인돌 함유 베타 효능제, 이의 제조 방법 및약제로서의 이의 용도
JP2006036730A (ja) 新規ピロール誘導体
IL134420A (en) AMINE INTERMEDIATES USEFUL FOR THE PREPARATION OF β3 ADRENERGIC RECEPTOR AGONISTS